콘텐츠로 건너뛰기
Merck

860638P

Avanti

C18 Glucosyl(β) Ceramide-d5

Avanti Research - A Croda Brand

동의어(들):

D-glucosyl-β-1,1′-N-stearoyl-D-erythro-sphingosine-d5

조직 및 계약 가격을 보려면 로그인를 클릭합니다.

크기 선택

보기 변경

제품정보 (DICE 배송 시 비용 별도)

실험식(Hill 표기법):
C42H76D5NO8
CAS 번호:
Molecular Weight:
733.13
MDL number:
UNSPSC Code:
12352100
NACRES:
NA.25
Assay:
>99% (TLC)
Form:
powder
기술 서비스
도움이 필요하신가요? 저희 숙련된 과학자 팀이 도와드리겠습니다.
도움 문의


제품 이름

C18 Glucosyl(β) Ceramide-d5, Avanti Research - A Croda Brand 860638P, powder

assay

>99% (TLC)

form

powder

packaging

pkg of 1 × 1 mg (860638P-1mg)

manufacturer/tradename

Avanti Research - A Croda Brand 860638P

shipped in

dry ice

storage temp.

−20°C

SMILES string

[H][C@](/C=C/CCCCCCCCCCCC([2H])(C([2H])([2H])[2H])[2H])(O)[C@@]([H])(NC(CCCCCCCCCCCCCCCCC)=O)CO[C@H](O1)[C@H](O)[C@@H](O)[C@@H]([C@H]1CO)O

InChI

1S/C42H81NO8/c1-3-5-7-9-11-13-15-17-18-20-22-24-26-28-30-32-38(46)43-35(34-50-42-41(49)40(48)39(47)37(33-44)51-42)36(45)31-29-27-25-23-21-19-16-14-12-10-8-6-4-2/h29,31,35-37,39-42,44-45,47-49H,3-28,30,32-34H2,1-2H3,(H,43,46)/b31-29+/t35-,36+,37+,39+,40-,4

InChI key

YMYQEDCYNANIPI-PFHCAOQOSA-N

Application

C18 Glucosyl(β) Ceramide-d5 has been used as an internal standard for the quantification of glucosylceramide, in the extracts from mouse cerebellum by liquid chromatography-tandem mass spectrometry.

Packaging

5 mL Amber Glass Screw Cap Vial (860638P-1mg)

Legal Information

Avanti Research is a trademark of Avanti Polar Lipids, LLC


저장 등급

11 - Combustible Solids

wgk

WGK 3

flash_point_f

No data available

flash_point_c

No data available



가장 최신 버전 중 하나를 선택하세요:

시험 성적서(COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our 문서 section.

도움이 필요하시면 연락하세요. 고객 지원 부서

이 제품을 이미 가지고 계십니까?

문서 라이브러리에서 최근에 구매한 제품에 대한 문서를 찾아보세요.

문서 라이브러리 방문



Victoria Schiffer et al.
PloS one, 15(1), e0227077-e0227077 (2020-01-14)
Gaucher disease is caused by a deficiency in glucocerebrosidase that can result in non-neuronal as well as neuronal symptoms. Common visceral symptoms are an increased organ size, specifically of the spleen, and glucosylceramide as well as glucosylsphingosine substrate accumulations as